Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
22
AUTL Quote, Financials, Valuation and Earnings
Last price:
$2.23
Seasonality move
:
-14.07%
Day range:
$2.20 - $2.35
52-week range:
$2.20 - $7.45
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.28x
Volume:
2.6M
Avg. volume:
2.2M
1-year change:
-58.36%
Market cap:
$609.4M
Revenue:
$1.7M
EPS (TTM):
-$1.22
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
$155K | -$0.22 | -61.82% | -46.14% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$20.5M | -$0.18 | 4199.24% | -9.44% | $3.50 |
|
BCYC
Bicycle Therapeutics PLC
|
$7M | -$0.78 | 16.38% | -23.21% | $33.36 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- |
|
DBVT
DBV Technologies SA
|
$1.1M | -$1.77 | -- | -59.89% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
$2.29 | -- | $609.4M | -- | $0.00 | 0% | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.60 | $3.50 | $154.8M | -- | $0.00 | 0% | 0.85x |
|
BCYC
Bicycle Therapeutics PLC
|
$14.68 | $33.36 | $1B | -- | $0.00 | 0% | 20.49x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$3.90 | -- | $2.3M | -- | $0.00 | 0% | 3.52x |
|
DBVT
DBV Technologies SA
|
$3.19 | -- | $65.4M | -- | $0.00 | 0% | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
$0.67 | -- | $5.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
-- | 4.339 | -- | 17.97x |
|
ADAP
Adaptimmune Therapeutics PLC
|
38.4% | 5.180 | 20.51% | 3.54x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.257 | -- | 16.82x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -0.555 | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -0.249 | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -0.755 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$14.7M | -55.22% | -67.8% | -38.33% | -$54.9M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$63.5M | -27.99% | -29.19% | -2026.05% | -$40.3M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | -- | -- |
|
DBVT
DBV Technologies SA
|
-- | -$30.3M | -- | -- | -- | -$22.9M |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
Autolus Therapeutics PLC vs. Competitors
-
Which has Higher Returns AUTL or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of -43.07%. Autolus Therapeutics PLC's return on equity of -80.74% beat Adaptimmune Therapeutics PLC's return on equity of -67.8%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M ADAPAdaptimmune Therapeutics PLC-- -$0.06 $129.9M -
What do Analysts Say About AUTL or ADAP?
Autolus Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 356.33%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $3.50 which suggests that it could grow by 274.78%. Given that Autolus Therapeutics PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Adaptimmune Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 2 0 ADAPAdaptimmune Therapeutics PLC4 2 0 -
Is AUTL or ADAP More Risky?
Autolus Therapeutics PLC has a beta of 1.984, which suggesting that the stock is 98.37% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.179, suggesting its more volatile than the S&P 500 by 117.863%.
-
Which is a Better Dividend Stock AUTL or ADAP?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or ADAP?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $40.9M. Autolus Therapeutics PLC's net income of -$82.1M is lower than Adaptimmune Therapeutics PLC's net income of -$17.6M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 0.85x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M ADAPAdaptimmune Therapeutics PLC0.85x -- $40.9M -$17.6M
-
Which has Higher Returns AUTL or BCYC?
Bicycle Therapeutics PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of -1898.43%. Autolus Therapeutics PLC's return on equity of -80.74% beat Bicycle Therapeutics PLC's return on equity of -29.19%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M BCYCBicycle Therapeutics PLC-- -$0.74 $831M -
What do Analysts Say About AUTL or BCYC?
Autolus Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 356.33%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $33.36 which suggests that it could grow by 127.27%. Given that Autolus Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 2 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is AUTL or BCYC More Risky?
Autolus Therapeutics PLC has a beta of 1.984, which suggesting that the stock is 98.37% more volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.196%.
-
Which is a Better Dividend Stock AUTL or BCYC?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BCYC?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are larger than Bicycle Therapeutics PLC quarterly revenues of $2.7M. Autolus Therapeutics PLC's net income of -$82.1M is lower than Bicycle Therapeutics PLC's net income of -$50.8M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 20.49x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M BCYCBicycle Therapeutics PLC20.49x -- $2.7M -$50.8M
-
Which has Higher Returns AUTL or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -80.74% beat Biodexa Pharmaceuticals PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M BDRXBiodexa Pharmaceuticals PLC-- -- -- -
What do Analysts Say About AUTL or BDRX?
Autolus Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 356.33%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 105.52%. Given that Autolus Therapeutics PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Autolus Therapeutics PLC is more attractive than Biodexa Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 2 0 BDRXBiodexa Pharmaceuticals PLC0 0 0 -
Is AUTL or BDRX More Risky?
Autolus Therapeutics PLC has a beta of 1.984, which suggesting that the stock is 98.37% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.
-
Which is a Better Dividend Stock AUTL or BDRX?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BDRX?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$82.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 3.52x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M BDRXBiodexa Pharmaceuticals PLC3.52x -- -- --
-
Which has Higher Returns AUTL or DBVT?
DBV Technologies SA has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -80.74% beat DBV Technologies SA's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M DBVTDBV Technologies SA-- -$1.60 -- -
What do Analysts Say About AUTL or DBVT?
Autolus Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 356.33%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that DBV Technologies SA has higher upside potential than Autolus Therapeutics PLC, analysts believe DBV Technologies SA is more attractive than Autolus Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 2 0 DBVTDBV Technologies SA0 0 0 -
Is AUTL or DBVT More Risky?
Autolus Therapeutics PLC has a beta of 1.984, which suggesting that the stock is 98.37% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.
-
Which is a Better Dividend Stock AUTL or DBVT?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or DBVT?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are larger than DBV Technologies SA quarterly revenues of --. Autolus Therapeutics PLC's net income of -$82.1M is lower than DBV Technologies SA's net income of -$30.4M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M DBVTDBV Technologies SA-- -- -- -$30.4M
-
Which has Higher Returns AUTL or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -522.15% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -80.74% beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics PLC-- -$0.31 $582M TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About AUTL or TCBP?
Autolus Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 356.33%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 349.17%. Given that Autolus Therapeutics PLC has higher upside potential than TC BioPharm (Holdings) PLC, analysts believe Autolus Therapeutics PLC is more attractive than TC BioPharm (Holdings) PLC.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics PLC7 2 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is AUTL or TCBP More Risky?
Autolus Therapeutics PLC has a beta of 1.984, which suggesting that the stock is 98.37% more volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AUTL or TCBP?
Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or TCBP?
Autolus Therapeutics PLC quarterly revenues are $10.1M, which are larger than TC BioPharm (Holdings) PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$82.1M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 0.02% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.7% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.65% over the past day.
